anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In one aspect, the disclosure provides a conjugate comprising an insulin molecule having an A-chain and a B-chain; an affinity ligand covalently bound to the A-chain; and a monovalent glucose binding agent covalently bound to the B-chain, wherein the affinity ligand competes with glucose for non-covalent binding with the monovalent glucose binding agent. In the absence of glucose, the monovalent glucose binding agent binds the affinity ligand to produce a "closed" inactive form of the insulin molecule. When free glucose is added, it competes with the affinity ligand for binding with the monovalent glucose binding agent to produce an "open" active form of the insulin molecule. The monovalent glucose binding agent and affinity ligand are covalently bound to the insulin molecule. The disclosure also provides methods of using these conjugates and methods of making these conjugates. In another aspect, the disclosure provides exemplary conjugates. The disclosure also provides alternative conjugates that are not necessarily activated by glucose.
INTRODUCTION: Sleep is a crucial determinant of maternal and fetal health, significantly impacting the well-being of both the mother and her developing fetus. Poor sleep quality, characterized by difficulties in falling asleep or staying asleep, can cause poor pregnancy outcome. Conversely, studies came with inconsistent result in the prevalence of poor sleep quality in different trimester of pregnancy. Therefore, this systematic review and meta-analysis study aimed to compare the prevalence of poor sleep quality in different trimesters.
METHOD: A systematic review and meta-analysis were done on published studies. Electronic data base search was done from PubMed, Hinari, Medline and Google Scholar. Data were extracted with Excel and the analysis were done using STATA version 17. Publication bias was assessed both graphically and statistically. I-square test was used to identify heterogeneity.
RESULT: In this meta-analysis, 38 studies that measured poor sleep quality using the Pittsburg Sleep Quality Index (PSQI ≥ 5) were included. The pooled prevalence of poor sleep quality was identified as 37.46% (95% CI: 29.26, 45.67) in the first trimester, 47.62% (95% CI: 42.23, 53.02) in the second trimester, and 60.05% (95% CI: 51.32, 68.78) in the third trimester.
CONCLUSION: This study identified a significant discrepancy in the prevalence of poor sleep quality, which increases as gestational age advances. Therefore, this discrepancy should be addressed, and additional support should be provided to pregnant women to help them achieve adequate sleep, especially as gestational age advances.
Safety and effectiveness have been established in pediatric liver transplant patients.

Liver Transplantation

Safety and efficacy in pediatric liver transplant patients less than 16 years of age are based on evidence from active controlled studies that included 56 pediatric patients, 31 of which received tacrolimus. Additionally, 122 pediatric patients were studied in an uncontrolled trial of tacrolimus in living related donor liver transplantation. Pediatric patients generally required higher doses of tacrolimus to maintain blood trough concentrations of tacrolimus similar to adult patients [see Dosage and Administration (2.3), Adverse Reactions (6.1), Clinical Pharmacology (12.3) and Clinical Studies (14.2)].

Additional pediatric use information is approved for Astellas Pharma US, Inc.’s Prograf (tacrolimus) products. However, due to Astellas Pharma US, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.
A 14-year-old boy presented after 2 months of vision loss, redness, and pain in the right eye, initially treated as anterior uveitis with topical corticosteroids. He had a 1-year history of T-cell acute lymphoblastic leukemia, which had been in remission for 6 months. On examination, visual acuity in the right eye was light perception, with 4+ anterior chamber cells, pupillary membrane, and an intumescent cataract. Ultrasound biomicroscopy (UBM) revealed a ciliary body mass and capsular bag rupture. After consultation with his oncologist, he received 10 radiotherapy sessions. At 1 month, UBM showed resolution of the mass. After 1 year of remission, the patient underwent pars plana vitrectomy, pupillary membranectomy, and placement of a scleral-fixated intraocular lens. Thirty months after surgery, visual acuity was 20/25. Leukemic infiltration of the ciliary body is a rare manifestation of the disease that is often misdiagnosed as uveitis.
The number of low back pain (LBP) cases is projected to increase to more than 800 million by 2050. To address the substantial burden of disease associated with this rise in prevalence, effective treatments are needed. While clinical practice guidelines (CPG) consistently recommend non-pharmacological therapies as first-line treatments, recommendations regarding manual therapy (MT) in treating low back pain vary. The goal of this narrative review was to critically summarize the available evidence for MT behind these recommendations, to scrutinize its mechanisms of action, and propose some actionable steps for clinicians on how this knowledge can be integrated into a person-centered approach. Despite disparate recommendations from CPG, MT is as effective as other available treatments and may be offered to patients with LBP, especially as part of a treatment package with exercise and education. Most of the effects of MT are not specific to the technique. MT and other interventions share several mechanisms of action that mediate treatment success. These mechanisms can encompass patients' expectations, prior experiences, beliefs and convictions, epistemic trust, and nonspecific contextual effects. Although MT is safer than opioids for patients with LBP, this alone is insufficient. Our goal is to encourage clinicians to shift away from outdated and refuted ideas in MT and embrace a person-centered approach rooted in a comprehensive biopsychosocial framework while incorporating patients' beliefs, addressing illness behaviors, and seeking to understand each patient's journey.
BACKGROUND: Elevated inflammatory cytokines in the periphery have been identified as active contributors to neuroinflammation and sympathetic overactivity in heart failure (HF). Yet, the exact mechanisms by which these cytokines breach the blood-brain barrier (BBB) to exert their effects on the brain remain elusive. Interleukin 17A has been linked to BBB disruption in various neurologic disorders, and its levels were significantly augmented in circulation and the brain in HF. The present study aimed to determine whether the BBB integrity was compromised within the hypothalamic paraventricular nucleus (PVN), and if so, whether interleukin 17A contributes to BBB disruption in myocardial infarction-induced HF.
METHODS AND RESULTS: Male Sprague-Dawley rats underwent coronary artery ligation to induce HF or sham surgery. Some HF rats received bilateral PVN microinjections of an interleukin 17 receptor A small interfering RNA or a scrambled small interfering RNA adeno-associated virus. Four weeks after coronary artery ligation, the permeability of the BBB was evaluated by intracarotid injection of fluorescent dyes (fluorescein isothiocyanate-dextran 10 kDa+rhodamine-dextran 70 kDa). Compared with sham-operated rats, HF rats exhibited an elevated extravasation of fluorescein isothiocyanate-dextran 10 kDa within the PVN but not in the brain cortex. The plasma interleukin 17A levels were positively correlated with fluorescein isothiocyanate 10 kDa extravasation in the PVN. The expression of caveolin-1, a transcytosis marker, was augmented, whereas the expression of tight junction proteins was diminished in HF rats. Interleukin 17 receptor A was identified within the endothelium of PVN microvessels. Treatment with interleukin 17 receptor A small interfering RNA led to a significant attenuation of fluorescein isothiocyanate 10 kDa extravasation in the PVN and reversed expression of caveolin-1 and tight junction-associated proteins in the PVN.
CONCLUSIONS: Collectively, these data indicate that BBB permeability within the PVN is enhanced in HF and is likely attributable to increased interleukin 17A/interleukin 17 receptor A signaling in the BBB endothelium, by promoting caveolar transcytosis and degradation of tight junction complexes.
The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
This invention relates to newly identified, polypeptides and polynucleotides encoding such polypeptides, which hereinafter are referred to as IGS5, to their use in therapy and in identifying compounds which may be stimulators and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides. The polypeptides and polynucleotides are related to the metalloprotease family and preferably of human type. The invention also relates to inhibiting or stimulating/activating the action of such polypeptides and polynucleotides, to a vector containing said polynucleotides and to a host cell containing such vector. The invention further relates to a method for screening compounds capable to act as a stimulator or inhibitor of said IGS5 enzyme. The Polypeptides of the present invention are of interest in the context of several dysfunctions, disorders or diseases. The Polypeptides of the present invention are in particular of interest in the context of cardiovascular diseases.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for treating brain glioma. For this purpose after tumour ablation glucocortocoids are introduced intramuscularly daily and radiotherapy is carried out. Before beginning irradiation and in process of treatment every 7-10 days blood serum is applied on transparent surface, dried at 20 - 25C and relative humidity 55 - 60% and microscopic image of blood serum fascies is analysed. If in sample in process of irradiation leaf-shaped structures appear or their number increases in comparison with sample before irradiation less than 2 times, additionally trental is introduced intravenously in dose 100-200 mg twice per week. If number of said structures in sample increases 2 times and more trental is introduced intravenously in dose 200-300 mg twice per week and actovegin is introduced in dose 400 mg daily. Medications are introduced before finishing course of radiotherapy. ^ EFFECT: increase of treatment efficiency and possibility to carry out complete course of radiotherapy due to individual control of state of microcirculatory brain bed and depth of its injuries, cause by radiotherapy, which allows to carry out their drug correction in due time in accordance with individual programme. ^ 4 dwg, 2 ex
The end tidal CO2 sensor is placed in the respiratory circuit and the monitor is visible to the resuscitation team. The resuscitation team is instructed to adjust ventilation to keep EtCO2 levels between 40-55.
A transparent toilet bar with an embedded decorative concentric pattern comprised of colored transparent soap formulations, and a method for producing the bar. The preferred embodiment of the bar is a transparent semi-circular rainbow pattern of three or more colors embedded in a transparent rectangular bar with a glittering agent. The preferred method of producing the rainbow is to pour a first color into a small circular mold and then to place that circular soap article into a larger mold and pour a second color around the soap article. A third concentric ring is created by repeating the process with a larger third mold. The finished disk is cut in half to create two rainbow soap articles. In the preferred embodiment of the method, all soap compositions are identical except for color or glitter additives.
Pectointercostal and ESP block will apply to the children after intubation. Totally bupivacain %0.25, 2.5 mg/kg will apply.
<P>PROBLEM TO BE SOLVED: To provide a cleanser which holds an excellent cleansing force, can also be used by patients of atopic dermatitis, contact dermatitis, or the like, can reduce an itch sense, and gives an excellent sense of use.  <P>SOLUTION: This liquid or pasty cleanser is characterized by containing a surfactant as a main cleansing component and an extract of Machilus Thunbergii in an amount of 10 to 50 wt.% based on the total amount of the cleanser. A toilet soap is characterized by containing the waste solvent extract of the Machilus Thunbergii or the bark or leaf powder of the Machilus Thunbergii in an amount of about 0.1 to 15 pts.wt. based on the total amount of the cleanser. These cleansers have each an itch sense-abating action.  <P>COPYRIGHT: (C)2004,JPO
PURPOSE:To obtain a calcium pharmaceutical preparation, using a calcium ingredient and ferrous chloride in combination and capable of promoting and improving the absorption of calcium from an alimentary canal. CONSTITUTION:This calcium pharmaceutical preparation is obtained by using a calcium ingredient and ferrous chloride in combination. The calcium and ferrous chloride are preferably blended at 1:[(1/1000) to 5/1000)] weight ratio of the calcium:ferrous chloride. The calcium ingredient used herein may be calcium carbonate, calcium phosphate, calcium hydroxide, etc., derived from minerals, e.g. limestone or milk of lime; shellfish calcium derived from oyster shells, shellfishes or corals, etc. ; crustaceans such as a crab, a lobster or a shrimp; algae such as sea tangle (Laminaria japonica Areschoug), hizikia (Hizikia fusiforme Okamura) or WAKAME seaweed (Undaria pinnatifida Suringar); bones of mammals or eggshells, etc. The ferrous chloride may be prepared by purifying a commercially available product. For example, a calcium absorbefacient separated from calcium of a sea urchin test may be used and a fraction containing the ferrous chloride may be separated and collected for use. The calcium pharmaceutical preparation can be produced into a medicine, a quasi-drug, a food, etc.
An antiviral composition comprising ground edible acorns or a solvent extract from ground edible acorns (GEAs), wherein the content of polyphenols or gallic acid is from 1-15 % w/w. The range of polyphenols or gallic acid may be 3-12 % w/w, or may be 6.7-8 % w/w. The polyphenols may comprise flavonoids, such as quercetin. The GEAs may be particles with a mass median diameter no greater than 0.25 mm. The composition may comprise dextrin or microcrystalline cellulose, where either are in a ratio to the GEAs from 1:10 to 1:1, and may also further comprise a magnesium salt of one or more fatty acids, where the combined dextrin, microcrystalline cellulose and magnesium salt of a fatty acid are in a ratio to the GEAs from 1:10 to 1:1. The composition may be in the form of a drink, comprising an aqueous extract of GEAs, and may further comprise a fruit juice comprising polyphenols. Also provided is a method of preparing a liquid antiviral composition, and a method of preparing a cookie dough composition. Also provided is a capsule or tablet for delivery of the antiviral composition, which may have 50-600 mg of polyphenols.
Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
EPRONTIA (topiramate) oral solution is available as a 25 mg/mL solution for oral administration.

Topiramate has the molecular formula C 12H 21NO 8S and a molecular weight of 339.36. Topiramate is designated chemically as 2,3:4,5-Di- O-isopropylidene-β-D-fructopyranose sulfamate and has the following structural formula: 

Topiramate is a white crystalline powder with a bitter taste. Topiramate is a sulfamate-substituted monosaccharide. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and having a pH of 9 to 10. It is freely soluble in acetone, chloroform, dimethylsulfoxide, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH of 6.3.

EPRONTIA oral solution is colorless to slightly yellow colored clear viscous liquid. EPRONTIA contains the following inactive ingredients: glycerin, methylparaben, mixed berry flavor, polyethylene glycol, propylparaben, and sucralose.
The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 2 (phone-based post-test counseling and referral), the CHV will provide the woman with a phone number which she may call or short message service (SMS) to receive post-test counseling and referral. If the study team does not receive a call or SMS from the woman within one week, our research assistant will phone and/or SMS the participant to provide phone-based post-test counseling and referral.
Two (2) women in each of cohorts 1 and 4, and two (2) men in cohort 2 will receive placebo every 2 weeks for a total of 6 doses. Two (2) women in each of cohorts 3 and 5, and two (2) men in cohort 6 will receive placebo every 4 weeks for a total of 3 doses. Six (6) women in cohort 7 will receive placebo every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of placebo; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
Participants received using the STM system TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
Subconcussive head impacts are associated with the development of acute and chronic cognitive deficits. We recently reported that high-frequency head impact (HFHI) causes chronic cognitive deficits in mice through synaptic changes. To better understand the mechanisms underlying HFHI-induced memory decline, we used TRAP2/Ai32 transgenic mice to enable visualization and manipulation of memory engrams. We labeled the fear memory engram in male and female mice exposed to an aversive experience and subjected them to sham or HFHI. Upon subsequent exposure to natural memory recall cues, sham, but not HFHI, mice successfully retrieved fearful memories. In sham mice the hippocampal engram neurons exhibited synaptic plasticity, evident in amplified AMPA:NMDA ratio, enhanced AMPA-weighted tau, and increased dendritic spine volume compared with nonengram neurons. In contrast, although HFHI mice retained a comparable number of hippocampal engram neurons, these neurons did not undergo synaptic plasticity. This lack of plasticity coincided with impaired activation of the engram network, leading to retrograde amnesia in HFHI mice. We validated that the memory deficits induced by HFHI stem from synaptic plasticity impairments by artificially activating the engram using optogenetics and found that stimulated memory recall was identical in both sham and HFHI mice. Our work shows that chronic cognitive impairment after HFHI is a result of deficiencies in synaptic plasticity instead of a loss in neuronal infrastructure, and we can reinstate a forgotten memory in the amnestic brain by stimulating the memory engram. Targeting synaptic plasticity may have therapeutic potential for treating memory impairments caused by repeated head impacts.
Our objective is to investigate the impact of an acute bout of resistance training on key signaling pathways involved in the regulation of muscle mass in moderate to severe COPD (FEV1 under 60% of predicted). Key proteins of signaling intramuscular pathways involved in protein synthesis and degradation will be measured before after 72 contractions of the quadriceps. The exercise protocol was designed to match the actual exercise prescription model use in the context of pulmonary rehabilitation. A squat, leg press and leg extension will be done at 80% of max with one minute rest between sets. A biopsy of the quadriceps will be done before and after exercise in order to measure phosphorylated kinases, total protein content and mRNA expressions. All our patients will undergo a thorough baseline assessment in pulmonary capacity, muscle force and body composition.
Participants received, in random order, a single dose of placebo or Gaboxadol with a two-week washout period between doses. The gaboxadol dosage selected for this study is 10 mg or Placebo as a single dose on each study visit (two at home and two in clinic).
PURPOSE:To prepare the SF-2354 substance capable of promoting the antibacterial activity of other antibiotic substances, by culturing a microbial strain belonging to Streptomyces genus and capable of producing Streptomyces substance. CONSTITUTION:Streptomyces sp. SF-2354 (FERM-P No.7769) belonging to Streptomyces genus is cultured in a medium containing nutrients assimilable by conventional microorganisms. The culture is carried out prefeably by liquid culture, especially by submerged culture under aerobic condition. Th objective novel antibiotic substance SF-2354 is separated from the culture product. The antibiotic substance is colorless amorphous powder having elemental composition of C50.57(wt)%, H 6.67%, N 15.14% and O 26.22%, and effective to promote the antibacterial activity of other antibiotic substances (e.g. fosfomycin, beta-lactam, etc.) in spice of its slight antibacterial activity. It is used mainly as a mixture with these antibiotic substances.
Single treatment (16000 µg by 20 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
The participants are treated with FASTFORWARDTM Bunion Correction system. The FASTFORWARDTM Bunion Correction system employed 3D printed titanium bone tether plate at second metatarsal. Due to the merit of 3D printing technology, the plate is designed to broadly distribute forces across bone to secure mechanical integrity of the bone. The FASTFORWARDTM Bunion Correction system has been cleared by the United States Food and Drug Administration.
Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. Oral morphine syrup is allowed to titrate the dose of TTS-fentanyl. The study duration will be 30 days after first patch application.